eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2024
vol. 16
 
Share:
Send email
Share:
abstract:
Case report

Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer

Trudy C. Wu
1
,
Alan Lee
1
,
Robert Suh
2
,
Talia C. Oughourlian
1
,
Fereidoun Abtin
2
,
Mary Ann Hagio
1
,
Sang-June Park
1
,
Albert J. Chang
1
,
Drew Moghanaki
1

  1. Department of Radiation Oncology, University of California, Los Angeles, CA, United States
  2. Department of Radiology, University of California, Los Angeles, CA, United States
J Contemp Brachytherapy 2024; 16, 2: 150–155
DOI: https://doi.org/10.5114/jcb.2024.139103
Online publish date: 2024/04/23
View full text Get citation
 
Patients with primary tumor progression after stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) have a second chance at complete tumor eradication with salvage local therapies, including lung resection, repeat course of SBRT, and percutaneous ablative therapies. In this paper, we presented our institution’s initial experience with percutaneous high-dose-rate (HDR) brachyablation for a relapsed stage I NSCLC that had been treated with SBRT 4.3 years earlier. Lung tumor measuring approximately 5 cm in maximum tumor dimension at the time of relapse was histopathologically confirmed to be persistent squamous cell carcinoma, and successfully treated with a single fraction of 24 Gy with HDR brachyablation. Treatment was delivered via two percutaneous catheters inserted under CT-guidance, and treated in less than 20 minutes. The patient was discharged home later the same day without the need for a chest tube, and has been monitored with serial surveillance scans every 3 to 6 months without evidence of further lung cancer progression or complications at 2.8 years post-HDR brachyablation procedure and 7.8 years after initial SBRT.
keywords:

lung cancer, high-dose-rate brachytherapy, stereotactic body radiation therapy, salvage

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.